share_log
  • Headlines
  • Korro Bio Has Submitted Regulatory Filing To Start Phase 1/2 Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency, First Participant Dosing Is Anticipated In Q1 Of 2025, With Interim Readout Is Expected In 2H Of 2025, And Completion Of Phase 1/2 Study...

Korro Bio Has Submitted Regulatory Filing To Start Phase 1/2 Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency, First Participant Dosing Is Anticipated In Q1 Of 2025, With Interim Readout Is Expected In 2H Of 2025, And Completion Of Phase 1/2 Study...

Benzinga ·  Nov 4 20:32

Korro Bio Has Submitted Regulatory Filing To Start Phase 1/2 Study Of KRRO-110 For Alpha-1 Antitrypsin Deficiency, First Participant Dosing Is Anticipated In Q1 Of 2025, With Interim Readout Is Expected In 2H Of 2025, And Completion Of Phase 1/2 Study Anticipated In 2026

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated